Yuyu Pharma유유제약

Yuyu Pharma has returned to profit over the trailing twelve months, but its share price is down over the past year and trades at a low valuation.

Yuyu Pharma, a long-established Korean drugmaker, reported trailing twelve-month revenue of ₩144.4B... wait, revenue of ₩144.4B is the figure in the data, so it is stated here as ₩144.4B with net income of ₩12.5B through H1 2026. The shares closed at ₩3,640 on 26 October 2026, down 12.8% over one year, and sit well below the 52-week high of ₩5,100.

What stands out

• Trailing revenue is about ₩144.4B with operating income of ₩13.2B (9.1% margin) and net income of ₩12.5B, a clear improvement on the losses recorded in 2021 to 2023.
• Revenue grew 5.8% in 2025 to ₩140.9B, but 2025 net income of ₩8.2B was below 2024's ₩8.7B, so profit has not risen in a straight line.
• The stock trades at about 4.6x trailing earnings and 0.4x book value, with a 3.2% dividend yield; peers such as Samsung Biologics and Alteogen trade at much higher multiples.
• The data includes a discounted cash flow fair value model with a base case of ₩4,067, a bear case of ₩1,491 and a bull case of ₩8,666; these are model outputs, not forecasts or targets.
• Recent headlines focus on new product launches and a 'Unicap' multi-dosage-form technology platform, with no financial impact quantified in the data.

What to watch

• Q3 2026 quarterly results, which are not yet in the data, to see whether margins hold near the trailing 9.1% level.
• Filings on the conversion and warrant exercise price adjustment from September 2026, which may affect share dilution; the data does not give the size of this effect.
• Foreign ownership is only 2.7% and was unchanged over 60 days, while retail investors were net sellers over the last 20 days; the data does not explain the cause.